Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.28 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 48.15% year-over-year to -$0.28; the TTM value through Dec 2025 reached -$1.53, up 65.46%, while the annual FY2025 figure was -$1.53, 65.46% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.28 in Q4 2025 per AMLX's latest filing, up from -$0.37 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.31 in Q2 2023 and bottomed at -$4.3 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.04, with a median of -$0.62 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 133.33% in 2023, then crashed 8850.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$4.3 in 2021, then skyrocketed by 85.59% to -$0.62 in 2022, then soared by 111.29% to $0.07 in 2023, then plummeted by 871.43% to -$0.54 in 2024, then soared by 48.15% to -$0.28 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.28 in Q4 2025, -$0.37 in Q3 2025, and -$0.46 in Q2 2025.